000169058 001__ 169058
000169058 005__ 20240229133637.0
000169058 0247_ $$2doi$$a10.1371/journal.pmed.1003616
000169058 0247_ $$2pmid$$apmid:34061847
000169058 0247_ $$2ISSN$$a1549-1277
000169058 0247_ $$2ISSN$$a1549-1676
000169058 0247_ $$2altmetric$$aaltmetric:106836091
000169058 037__ $$aDKFZ-2021-01216
000169058 041__ $$aEnglish
000169058 082__ $$a610
000169058 1001_ $$0P:(DE-He78)62b0f1b5eccef2b5f2e55b7f13ccde6d$$aXu, Xing$$b0$$eFirst author
000169058 245__ $$aRisk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study.
000169058 260__ $$aLawrence, Kan.$$bPLoS$$c2021
000169058 3367_ $$2DRIVER$$aarticle
000169058 3367_ $$2DataCite$$aOutput Types/Journal article
000169058 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1637231031_29527
000169058 3367_ $$2BibTeX$$aARTICLE
000169058 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169058 3367_ $$00$$2EndNote$$aJournal Article
000169058 500__ $$a#EA:C120#LA:C120#
000169058 520__ $$aEvidence-based guidance for starting ages of screening for first-degree relatives (FDRs) of patients with prostate cancer (PCa) to prevent stage III/IV or fatal PCa is lacking in current PCa screening guidelines. We aimed to provide evidence for risk-adapted starting age of screening for relatives of patients with PCa.In this register-based nationwide cohort study, all men (aged 0 to 96 years at baseline) residing in Sweden who were born after 1931 along with their fathers were included. During the follow-up (1958 to 2015) of 6,343,727 men, 88,999 were diagnosed with stage III/IV PCa or died of PCa. The outcomes were defined as the diagnosis of stage III/IV PCa or death due to PCa, stratified by age at diagnosis. Using 10-year cumulative risk curves, we calculated risk-adapted starting ages of screening for men with different constellations of family history of PCa. The 10-year cumulative risk of stage III/IV or fatal PCa in men at age 50 in the general population (a common recommended starting age of screening) was 0.2%. Men with ≥2 FDRs diagnosed with PCa reached this screening level at age 41 (95% confidence interval (CI): 39 to 44), i.e., 9 years earlier, when the youngest one was diagnosed before age 60; at age 43 (41 to 47), i.e., 7 years earlier, when ≥2 FDRs were diagnosed after age 59, which was similar to that of men with 1 FDR diagnosed before age 60 (41 to 45); and at age 45 (44 to 46), when 1 FDR was diagnosed at age 60 to 69 and 47 (46 to 47), when 1 FDR was diagnosed after age 69. We also calculated risk-adapted starting ages for other benchmark screening ages, such as 45, 55, and 60 years, and compared our findings with those in the guidelines. Study limitations include the lack of genetic data, information on lifestyle, and external validation.Our study provides practical information for risk-tailored starting ages of PCa screening based on nationwide cancer data with valid genealogical information. Our clinically relevant findings could be used for evidence-based personalized PCa screening guidance and supplement current PCa screening guidelines for relatives of patients with PCa.
000169058 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169058 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169058 7001_ $$0P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aKharazmi, Elhamalsadat$$b1$$eFirst author
000169058 7001_ $$0P:(DE-He78)834e8bc4d74592e3b999100c157215f5$$aTian, Yu$$b2
000169058 7001_ $$0P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aMukama, Trasias$$b3
000169058 7001_ $$00000-0001-8031-279X$$aSundquist, Kristina$$b4
000169058 7001_ $$00000-0001-7228-5015$$aSundquist, Jan$$b5
000169058 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6
000169058 7001_ $$0P:(DE-He78)b510b884502b619724039bf33fdae68a$$aFallah, Mahdi$$b7$$eLast author
000169058 773__ $$0PERI:(DE-600)2164823-2$$a10.1371/journal.pmed.1003616$$gVol. 18, no. 6, p. e1003616 -$$n6$$pe1003616 -$$tPLoS medicine$$v18$$x1549-1676$$y2021
000169058 909CO $$ooai:inrepo02.dkfz.de:169058$$pVDB
000169058 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)62b0f1b5eccef2b5f2e55b7f13ccde6d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169058 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169058 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)834e8bc4d74592e3b999100c157215f5$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169058 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169058 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000169058 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b510b884502b619724039bf33fdae68a$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000169058 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169058 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169058 9141_ $$y2021
000169058 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS MED : 2019$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-01-27
000169058 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bPLOS MED : 2019$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000169058 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000169058 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000169058 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000169058 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000169058 980__ $$ajournal
000169058 980__ $$aVDB
000169058 980__ $$aI:(DE-He78)C120-20160331
000169058 980__ $$aI:(DE-He78)C070-20160331
000169058 980__ $$aI:(DE-He78)HD01-20160331
000169058 980__ $$aUNRESTRICTED